what is a klow stack KLOW Stack Peptide | Synergy
Description
No clinical safety profile for BPC-157 or PDA in humans has been established through completed Phase 1 trials
Microbiota-derived SCFA can induce the release of incretins, including peptide tyrosine-tyrosine (PYY) and GLP-1, which modulate hunger and glucose metabolism 59
Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation
Basic six therapeutic principles of IEM include: (1) substrate reduction therapy (as in PKU), (2) removal of toxic metabolites (e.g., urea cycle disorders), (3) product supplementation (e.g., cerebral creatine deficiency disorders), (4) stimulating of deficient enzyme activity (e.g., B 6 supplementation in CBS deficiency), (5) enzyme replacement therapy (e.g., in LINCL) or 6) organ transplantation (in some cases of UCD and AIP)
